MCID: HMT002
MIFTS: 64

Hematologic Cancer

Categories: Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Hematologic Cancer

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 37 12 51 14
Hematologic Neoplasms 41 69
Hematologic Neoplasm 12 28
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematologic Malignancies 51
Hematopoietic Neoplasms 69
Hematologic Malignancy 12
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2531
MeSH 41 D019337
NCIt 46 C27134
SNOMED-CT 64 414388001 414644002

Summaries for Hematologic Cancer

Disease Ontology : 12 An immune system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasms, is related to platelet disorder, familial, with associated myeloid malignancy and mast cell neoplasm. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant 6), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include the hematological system, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Related Diseases for Hematologic Cancer

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 platelet disorder, familial, with associated myeloid malignancy 32.8 ETV6 RUNX1
2 mast cell neoplasm 32.2 IL2 IL3 KIT
3 myeloproliferative neoplasm 32.1 ABL1 ETV6 JAK2
4 bone marrow cancer 31.9 ABL1 CSF2 CSF3 ETV6 FLT3 IL3
5 leukemia 29.8 ABL1 CSF2 ETV6 FLT3 JAK2 KIT
6 myeloma, multiple 29.8 ABCB1 CSF2 CSF3
7 myeloid leukemia 29.7 ABL1 CSF2 ETV6 FLT3 IL3 KIT
8 leukemia, acute myeloid 29.0 ABCB1 ABL1 CDKN2B CSF2 CSF3 ETV6
9 refractory hematologic cancer 12.3
10 central nervous system hematologic cancer 12.2
11 myeloproliferative/lymphoproliferative neoplasms, familial 11.6
12 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 11.0
13 systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 11.0
14 pulmonary alveolar proteinosis, acquired 10.8
15 lymphoma 10.8
16 central nervous system leukemia 10.8
17 central nervous system lymphoma 10.8
18 histiocytic and dendritic cell cancer 10.8
19 refractory hairy cell leukemia 10.8
20 acquired pure red cell aplasia 10.8
21 acute myeloblastic leukemia without maturation 10.8 FLT3 NPM1
22 refractory anemia 10.7 IL3 JAK2 RUNX1
23 neutrophilia, hereditary 10.7 CSF2 FLT3 PTHLH
24 acute myeloblastic leukemia with maturation 10.7 FLT3 KIT NPM1
25 ring chromosome 21 10.7 ETV6 KMT2A
26 necrobiotic xanthogranuloma 10.7
27 hypereosinophilic syndrome, idiopathic 10.7 IL3 KIT WT1
28 8p11 myeloproliferative syndrome 10.7 FLT3 KIT RUNX1
29 childhood leukemia 10.7 ABL1 ETV6 KMT2A RUNX1
30 atypical chronic myeloid leukemia 10.7 ABL1 JAK2 RUNX1
31 congenital mesoblastic nephroma 10.7 ETV6 KIT WT1
32 aleukemic leukemia cutis 10.7 FLT3 NPM1 RUNX1
33 testicular gonadoblastoma 10.7 KIT WT1
34 lymphoid leukemia 10.7 ETV6 KMT2A RUNX1 RUNX1T1
35 maxillary sinus adenoid cystic carcinoma 10.7 IL2 KIT
36 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.7 FLT3 KIT RUNX1 RUNX1T1
37 felty syndrome 10.7 CSF2 CSF3 IL3
38 chronic eosinophilic leukemia 10.7 ABL1 FLT3 KIT WT1
39 megakaryocytic leukemia 10.7 CSF2 IL3 JAK2 RUNX1
40 engraftment syndrome 10.7 ABCB1 CSF2 CSF3
41 cyclic neutropenia 10.7 CSF2 CSF3 IL3
42 cytogenetically normal acute myeloid leukemia 10.7 FLT3 KMT2A NPM1 WT1
43 dysgerminoma of ovary 10.7 KIT PTHLH WT1
44 chronic myelomonocytic leukemia 10.7 ETV6 FLT3 JAK2 KIT RUNX1
45 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.7 ETV6 FLT3 KIT KMT2A RUNX1
46 myeloid sarcoma 10.7 FLT3 KIT KMT2A NPM1
47 acute biphenotypic leukemia 10.7 KMT2A MLLT10
48 granulocytopenia 10.7 CSF2 CSF3 IL3
49 leukemia, acute monocytic 10.7 KMT2A MLLT10 NUP98
50 malignant mesenchymoma 10.7 ETV6 KIT WT1

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer

Symptoms & Phenotypes for Hematologic Cancer

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.44 ETV6 JAK2 FLT3 IL2 ABCB1 CSF2
2 growth/size/body region MP:0005378 10.43 IL2 ETV6 JAK2 FLT3 ENG ABCB1
3 cardiovascular system MP:0005385 10.39 IL2 ETV6 ENG ABCB1 CSF2 ABL1
4 cellular MP:0005384 10.38 IL2 ETV6 JAK2 FLT3 CDKN2B CSF2
5 immune system MP:0005387 10.38 IL2 ETV6 JAK2 FLT3 CDKN2B ABCB1
6 homeostasis/metabolism MP:0005376 10.34 ENG IL2 ETV6 JAK2 FLT3 CDKN2B
7 mortality/aging MP:0010768 10.33 IL2 ETV6 JAK2 FLT3 ENG CDKN2B
8 endocrine/exocrine gland MP:0005379 10.31 IL2 ETV6 JAK2 FLT3 CDKN2B ABCB1
9 embryo MP:0005380 10.29 ETV6 JAK2 ENG CSF2 ABL1 NUP98
10 integument MP:0010771 10.23 ETV6 JAK2 ENG CDKN2B CSF2 CSF3
11 digestive/alimentary MP:0005381 10.16 ENG IL2 ETV6 ABCB1 ABL1 KIT
12 neoplasm MP:0002006 10.11 IL2 ETV6 JAK2 FLT3 CSF2 CDKN2B
13 liver/biliary system MP:0005370 10.09 IL2 JAK2 ABCB1 ABL1 KMT2A KIT
14 no phenotypic analysis MP:0003012 10.02 IL2 ETV6 FLT3 CDKN2B ABCB1 KMT2A
15 normal MP:0002873 9.91 ENG ETV6 ABL1 JAK2 KMT2A KIT
16 renal/urinary system MP:0005367 9.7 CDKN2B CSF2 CSF3 KMT2A KIT PTHLH
17 reproductive system MP:0005389 9.65 IL2 JAK2 CDKN2B ABCB1 CSF2 KMT2A
18 respiratory system MP:0005388 9.23 ENG IL2 CSF2 ABL1 KIT PTHLH

Drugs & Therapeutics for Hematologic Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 45 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Arranon 17 45 NELARABINE GlaxoSmithKline October 2005
3
Zydelig 17 45 IDELALISIB Gilead July 2014

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 506)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
3 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Colistin Approved Phase 4 1066-17-7, 1264-72-8 5311054
6
Protein C Approved Phase 4,Phase 2
7
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 179324-69-7 387447 93860
8
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
9
Caspofungin Approved Phase 4,Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
10
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 1,Phase 2 215647-85-1, 99210-65-8
11 Etiracetam Investigational Phase 4 33996-58-6
12 Anticonvulsants Phase 4,Phase 1,Phase 2
13 Nootropic Agents Phase 4
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
22 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
26 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Anticoagulants Phase 4,Phase 2,Phase 3,Phase 1
28 Drotrecogin alfa activated Phase 4
29 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Proteasome Inhibitors Phase 4,Phase 2,Phase 1
31 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 1
32 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Hydroxyitraconazole Phase 4
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
35 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
37 Echinocandins Phase 4,Phase 2
38 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
39 interferons Phase 4,Phase 3,Phase 2,Phase 1
40 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
41 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
42 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
43
Busulfan Approved, Investigational Phase 2, Phase 3, Phase 1 55-98-1 2478
44
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
45
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
46
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
47
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
48
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
49
Vidarabine Approved, Investigational Phase 3,Phase 2,Phase 1 24356-66-9 21704 32326
50
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show top 50) (show all 833)

# Name Status NCT ID Phase Drugs
1 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
2 A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM) Completed NCT02966457 Phase 4 Colistimethate Sodium
3 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
4 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4 bortezomib
6 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4 Bortezomib
7 The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants Completed NCT01021683 Phase 4 Itraconazole
8 A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Recruiting NCT02895529 Phase 4 Itraconazole;Caspofungin
9 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Recruiting NCT02634294 Phase 4 Peg interferon alfa-2b
10 HPV Antibody Response After GARDASIL 9 Vaccination in Participants After Allogeneic Stem Cell Transplantation Recruiting NCT03023631 Phase 4
11 SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients Terminated NCT01222819 Phase 4 filgrastim
12 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
13 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
14 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
15 Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
16 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
17 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
18 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
19 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
20 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
21 Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Completed NCT01767467 Phase 3 Placebo
22 Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed NCT00044759 Phase 3 Piperacillin/Tazobactam (Tazocin)
23 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3
24 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
25 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients Completed NCT00824993 Phase 3 Ibandronate;Vitamin Supplements
26 Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy Completed NCT01435200 Phase 3 Intravenous iron
27 Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01237639 Phase 3
28 A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Completed NCT00300664 Phase 2, Phase 3 Human Growth hormone
29 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
30 INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant Completed NCT01602211 Phase 3
31 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed NCT00750737 Phase 3 Posaconazole;ABLC
32 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
33 A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients Completed NCT01769170 Phase 3 Brincidofovir (CMX001)
34 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
35 Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT02229539 Phase 3 doxepin hydrochloride oral solution;DLA (diphenhydramine, lidocaine and antacids) rinse
36 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Completed NCT02116530 Phase 3 Olanzapine;Chemotherapy (cisplatin or cyclophosphamide and doxorubicin);Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
37 Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed NCT01080391 Phase 3 Dexamethasone;Lenalidomide;Carfilzomib
38 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed NCT00075829 Phase 3 Thalidomide;Dexamethasone
39 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
40 PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00048230 Phase 3 bortezomib
41 Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) Completed NCT01410227 Phase 3 Placebo
42 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
43 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
44 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
45 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
46 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
47 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
48 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
49 TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia Recruiting NCT03136445 Phase 3 Tranexamic acid (TXA).;Placebo
50 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Recruiting NCT02178683 Phase 3 Tacrolimus and MMF.

Search NIH Clinical Center for Hematologic Cancer

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hematologic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hematologic Cancer:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Hematologic Cancer:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Umbilical cord blood-derived hematopoietic progenitor cells (Allocord) PMIDs: 11953027
Peripheral blood-derived hematopoietic stem cells
Umbilical cord blood-derived hematopoietic progenitor cells (Ducord) PMIDs: 22698485 21810098 23711284 21277377
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 20676147

Cochrane evidence based reviews: hematologic neoplasms

Genetic Tests for Hematologic Cancer

Genetic tests related to Hematologic Cancer:

# Genetic test Affiliating Genes
1 Hematologic Neoplasm 28

Anatomical Context for Hematologic Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Hematologic Cancer:

18
The Hematological System

MalaCards organs/tissues related to Hematologic Cancer:

38
Bone, Bone Marrow, T Cells, Lung, Breast, Myeloid, B Cells

Publications for Hematologic Cancer

Articles related to Hematologic Cancer:

(show top 50) (show all 55)
# Title Authors Year
1
Pre- and post-diagnosis physical activity, television viewing, and mortality among hematologic cancer survivors. ( 29385194 )
2018
2
Feasibility and preliminary efficacy of an exercise telephone counseling intervention for hematologic cancer survivors: a phase II randomized controlled trial. ( 29411314 )
2018
3
Correlates of meeting the combined and independent aerobic and strength exercise guidelines in hematologic cancer survivors. ( 28351397 )
2017
4
Body Image Discomfort of Adolescent and Young Adult Hematologic Cancer Survivors. ( 28112547 )
2017
5
Living with hematologic cancer: Recommendations, solutions. ( 28696193 )
2017
6
Childhood hematologic cancer and residential proximity to oil and gas development. ( 28199334 )
2017
7
Psychological distress, chronic conditions and quality of life in elderly hematologic cancer patients: study protocol of a prospective study. ( 29070033 )
2017
8
Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): Uncommon, with improved survival but still deadly often. ( 28919347 )
2017
9
Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. ( 28778967 )
2017
10
Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? ( 27282880 )
2016
11
Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls. ( 26763882 )
2016
12
Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. ( 27400009 )
2016
13
Understanding strength exercise intentions and behavior in hematologic cancer survivors: an analysis of the intention-behavior gap. ( 27052642 )
2016
14
Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners. ( 27987096 )
2016
15
Cancer Care Burden among Primary Family Caregivers of Iranian Hematologic Cancer Patients. ( 26225701 )
2015
16
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B for Primary Therapy of Invasive Aspergillosis among High-Risk Hematologic Cancer Patients in Brazil. ( 26534377 )
2015
17
Survivorship Care Plans and Treatment Summaries a8"in Adult Patients With Hematologic Cancer: a8"An Integrative Literature Review. ( 25901380 )
2015
18
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin for Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Saudi Arabia. ( 26533739 )
2015
19
Hospitalization risk according to geriatric assessment and laboratory parameters in elderly hematologic cancer patients. ( 25684525 )
2015
20
Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. ( 26310541 )
2015
21
Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia. ( 25193462 )
2014
22
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. ( 24813251 )
2014
23
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. ( 24645687 )
2014
24
The falling incidence of hematologic cancer after heart transplantation. ( 25100534 )
2014
25
The microfluidic multitrap nanophysiometer for hematologic cancer cell characterization reveals temporal sensitivity of the calcein-AM efflux assay. ( 24873950 )
2014
26
Internet-based program for coping with cancer: a randomized controlled trial with hematologic cancer patients. ( 22565413 )
2013
27
Confirmation of the reported association of clonal chromosomal mosaicism with an increased risk of incident hematologic cancer. ( 23533652 )
2013
28
Evaluation of MycAssaya8c Aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer. ( 23620764 )
2013
29
Xist RNA is a potent suppressor of hematologic cancer in mice. ( 23415223 )
2013
30
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. ( 22622039 )
2012
31
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. ( 22099500 )
2012
32
Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis. ( 22166040 )
2012
33
p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. ( 23029260 )
2012
34
Improving access to information and support for patients with less common cancers: hematologic cancer patients' views about Web-based approaches. ( 22189354 )
2011
35
Physical activity and hematologic cancer prevention. ( 21113763 )
2011
36
Evolving information priorities of hematologic cancer survivors, caregivers, and other relatives. ( 20119694 )
2010
37
Mesial temporal sclerosis as a complication of hematologic cancer. ( 19434437 )
2009
38
Femoral resurfacing in young patients with hematologic cancer and osteonecrosis. ( 18679763 )
2008
39
Phase 3 trials suggest ways to improve current hematologic cancer therapies. ( 18252877 )
2008
40
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. ( 18344563 )
2008
41
Managed care considerations: hematologic cancer as a chronic disease. ( 19119536 )
2008
42
Posaconazole prophylaxis in hematologic cancer. ( 17526089 )
2007
43
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. ( 17607669 )
2007
44
Posaconazole prophylaxis in hematologic cancer. ( 17526091 )
2007
45
Posaconazole prophylaxis in hematologic cancer. ( 17526090 )
2007
46
Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. ( 17516403 )
2007
47
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. ( 17683622 )
2007
48
Posaconazole prophylaxis in hematologic cancer. ( 17522407 )
2007
49
Patient-rated emotional and physical functioning among hematologic cancer patients during hospitalization for stem-cell transplantation. ( 15580279 )
2005
50
In vitro chemosensitivity testing of hematological cancer patients: detection of ornithine decarboxylase. ( 12528799 )
2003

Variations for Hematologic Cancer

ClinVar genetic disease variations for Hematologic Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic/Likely pathogenic rs267606706 GRCh37 Chromosome 11, 119148891: 119148891
2 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
3 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
4 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
5 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913615 GRCh37 Chromosome 1, 43815009: 43815009
6 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 GRCh37 Chromosome 11, 119148930: 119148930
7 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh38 Chromosome 12, 11869601: 11869601
8 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh38 Chromosome 12, 11884541: 11884541
9 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh37 Chromosome 12, 12038902: 12038902

Expression for Hematologic Cancer

Search GEO for disease gene expression data for Hematologic Cancer.

Pathways for Hematologic Cancer

Pathways related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 ABL1 CDKN2B CSF2 CSF3 FLT3 IL2
2
Show member pathways
13.31 CSF2 CSF3 FLT3 IL2 IL3 JAK2
3
Show member pathways
13.24 CSF2 CSF3 FLT3 IL2 IL3 JAK2
4
Show member pathways
12.89 CDKN2B CSF2 FLT3 IL3 JAK2 KIT
5
Show member pathways
12.86 CSF3 FLT3 IL2 IL3 JAK2 KIT
6 12.53 ABL1 CDKN2B FLT3 IL2 IL3 JAK2
7 12.45 IL2 IL3 JAK2 KIT RUNX1 RUNX1T1
8
Show member pathways
12.26 CSF2 CSF3 IL2 IL3 JAK2
9
Show member pathways
12.03 CSF2 IL2 IL3 JAK2
10 12 ABL1 FLT3 JAK2 KIT NPM1
11
Show member pathways
11.76 CSF2 CSF3 JAK2
12 11.75 ABL1 IL2 IL3 JAK2
13 11.71 CSF2 CSF3 FLT3 IL3 KIT
14 11.68 IL2 KIT RUNX1
15
Show member pathways
11.66 CSF2 IL2 IL3
16 11.66 CSF2 FLT3 IL2 KIT
17 11.59 ABL1 IL2 WT1
18 11.57 ABCB1 ENG NPM1
19 11.56 CSF2 CSF3 ENG FLT3 IL2 IL3
20
Show member pathways
11.54 ABCB1 ABL1 KIT
21 11.49 CSF2 ETV6 FLT3 IL3 KMT2A RUNX1
22 11.35 CSF2 CSF3 IL3 RUNX1
23 11.1 CSF2 CSF3 IL2 IL3
24 11.03 CSF2 CSF3 IL2 IL3
25 10.89 CSF2 CSF3 FLT3 IL2 IL3 KIT

GO Terms for Hematologic Cancer

Cellular components related to Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.32 ABL1 JAK2 KMT2A MLLT10 NPM1 NUP98

Biological processes related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.98 CSF2 CSF3 IL2 IL3 PTHLH
2 negative regulation of cell proliferation GO:0008285 9.93 CDKN2B JAK2 KMT2A NPM1 PTHLH WT1
3 regulation of cell proliferation GO:0042127 9.9 ABL1 CSF2 JAK2 KIT
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.9 CDKN2B CSF3 ENG ETV6 IL2 KMT2A
5 MAPK cascade GO:0000165 9.88 CSF2 IL2 IL3 JAK2 KIT
6 protein autophosphorylation GO:0046777 9.86 ABL1 FLT3 JAK2 KIT
7 regulation of hematopoietic stem cell differentiation GO:1902036 9.81 ABL1 KMT2A RUNX1
8 hemopoiesis GO:0030097 9.77 FLT3 KIT RUNX1
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 ABL1 CSF3 IL3 JAK2
10 peptidyl-tyrosine phosphorylation GO:0018108 9.73 ABL1 CSF2 FLT3 IL3 JAK2 KIT
11 cytokine-mediated signaling pathway GO:0019221 9.72 CSF3 FLT3 IL3 JAK2 KIT
12 spleen development GO:0048536 9.67 ABL1 CDKN2B KMT2A
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 CSF3 FLT3 JAK2 KIT
14 regulation of regulatory T cell differentiation GO:0045589 9.63 IL2 RUNX1
15 negative regulation of cell-cell adhesion GO:0022408 9.62 ABL1 JAK2
16 hematopoietic stem cell proliferation GO:0071425 9.62 ETV6 RUNX1
17 dendritic cell differentiation GO:0097028 9.61 CSF2 FLT3
18 regulation of myeloid cell differentiation GO:0045637 9.61 CSF2 RUNX1
19 positive regulation of cell proliferation GO:0008284 9.61 CSF2 CSF3 FLT3 IL2 IL3 JAK2
20 negative regulation of heart contraction GO:0045822 9.58 IL2 JAK2
21 embryonic hemopoiesis GO:0035162 9.58 IL3 KIT KMT2A
22 regulation of cytokine-mediated signaling pathway GO:0001959 9.57 IL3 RUNX1
23 myeloid progenitor cell differentiation GO:0002318 9.55 FLT3 KIT
24 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.52 ENG KIT
25 neutrophil differentiation GO:0030223 9.51 CSF2 CSF3
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.1 CSF2 FLT3 IL2 IL3 JAK2 KIT
27 transcription by RNA polymerase II GO:0006366 10.01 ETV6 KMT2A NPM1 NUP98 RUNX1 WT1

Molecular functions related to Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 CSF2 CSF3 IL2 IL3
2 growth factor activity GO:0008083 9.46 CSF2 CSF3 IL2 IL3
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.35 CSF2 IL2 IL3 JAK2 KIT
4 peptide hormone receptor binding GO:0051428 9.32 JAK2 PTHLH
5 protein tyrosine kinase activity GO:0004713 9.1 ABL1 CSF2 FLT3 IL3 JAK2 KIT
6 protein binding GO:0005515 10.3 ABCB1 ABL1 CDKN2B CSF2 ENG ETV6

Sources for Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....